for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bavarian Nordic A/S

BAVA.CO

Latest Trade

219.20DKK

Change

2.60(+1.20%)

Volume

182,697

Today's Range

214.40

 - 

219.20

52 Week Range

103.20

 - 

234.60

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Bavarian Nordic Signs Contracts Worth EUR 11 Mln

Jan 5 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::BAVARIAN NORDIC TO SUPPLY SMALLPOX VACCINES TO THREE EUROPEAN COUNTRIES.HAS ENTERED INTO CONTRACTS WITH THREE EUROPEAN GOVERNMENTS FOR SUPPLY OF IMVANEX(®) SMALLPOX VACCINE.COMBINED VALUE OF CONTRACTS IS EUR 11 MILLION THAT WILL BE REVENUE RECOGNIZED DURING FIRST HALF OF 2021, WHERE DELIVERIES ARE EXPECTED TO OCCUR.

Bavarian Nordic Announces Results From Phase 2 Of BN-Brachyury In Chordoma

Dec 18 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::REG-BAVARIAN NORDIC ANNOUNCES TOP-LINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF BN-BRACHYURY IN CHORDOMA.REG-BAVARIAN NORDIC ANNOUNCES TOP-LINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF BN-BRACHYURY IN CHORDOMA.STUDY SHOWED SIGNS OF CLINICAL ACTIVITY, BUT FAILED TO MEET PRIMARY ENDPOINT OF PHASE 2 STUDY.TWO ONGOING PHASE 1 TRIALS ARE EXPLORING INTRAVENOUS ADMINISTRATION OF TWO DIFFERENT MVA-BASED BRACHYURY-TARGETING INVESTIGATIONAL PRODUCTS IN CHORDOMA..WHILE STUDY FAILED TO MEET ITS PRIMARY ENDPOINT, IT PROVIDED EVIDENCE OF CLINICAL ACTIVITY..ATIENTS WERE MONITORED OVER A PERIOD OF 12 MONTHS AFTER RADIATION THERAPY, A TIMEFRAME DURING WHICH HISTORICAL CONTROLS SHOW AN OBJECTIVE RESPONSE RATE (ORR) OF LESS THAN 5% WITH RADIATION ALONE..OVERALL GOAL OF STUDY WAS TO ACHIEVE FOUR PATIENTS WITH OBJECTIVE RESPONSES, CORRESPONDING TO AN ORR OF APPROXIMATELY 14% FOR ALL PATIENTS ENROLLED..

Bavarian Nordic Secures Second Part Of Smallpox Vaccine Order From U.S. Government

Dec 16 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::BAVARIAN NORDIC SECURES SECOND PART OF SMALLPOX VACCINE ORDER FROM U.S. GOVERNMENT.BAVARIAN NORDIC- U.S. BARDA EXERCISED OPTION COVERING MAJORITY OF SECOND YEAR OF PERFORMANCE UNDER $200 MILLION ORDER FOR JYNNEOS AWARDED IN APRIL 2020.BAVARIAN-FIRST $106 MILLION COVERED BOTH MANUFACTURING OF BULK VACCINE & SUPPLY OF LIQUID-FROZEN JYNNEOS DOSES, WAS SECURED UPON CONTRACT AWARD LAST APRIL.WITH CURRENT OPTION, BARDA IS COMMITTING TO AN ADDITIONAL USD $83 MILLION FOR PROCUREMENT OF MORE BULK SMALLPOX VACCINE.OPTIONS EXTEND CONTRACT AWARDED TO BAVARIAN NORDIC IN 2017.

Bavarian Nordic Says Health Canada Expands Approval Imvamune

Nov 12 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::HEALTH CANADA EXTENDS APPROVAL OF IMVAMUNE TO IMMUNIZATION AGAINST MONKEYPOX AND ORTHOPOX VIRUSES.HEALTH CANADA HAS EXPANDED APPROVAL OF COMPANY'S NON-REPLICATING SMALLPOX VACCINE, IMVAMUNE(®).

Bavarian Nordic Q3 EBITDA At DKK 163 Million

Nov 11 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::REG-BAVARIAN NORDIC ANNOUNCES INTERIM RESULTS FOR THE FIRST NINE MONTHS OF 2020.REG-BAVARIAN NORDIC ANNOUNCES INTERIM RESULTS FOR THE FIRST NINE MONTHS OF 2020.COMPANY RAISES ITS EBITDA GUIDANCE FROM DKK 675 MILLION TO DKK 725 MILLION AND UPGRADES YEAR-END GUIDANCE ON CASH..Q3 REVENUE DKK 558 MILLION VERSUS DKK 144 MILLION YEAR AGO.Q3 EBITDA DKK 163 MILLION VERSUS LOSS DKK 82 MILLION YEAR AGO.SECURITIES, CASH AND CASH EQUIVALENTS AT YEAR-END IS NOW EXPECTED TO BE DKK 1,600 MILLION, DKK 100 MILLION HIGHER THAN PREVIOUSLY GUIDED, AS RESULT OF IMPROVED EBITDA AND CHANGES IN WORKING CAPITAL ASSUMPTIONS.FY EBITDA GUIDANCE RAISED FROM DKK 675 MILLION TO DKK 725 MILLION.MARKETS FOR RABIPUR/RABAVERT AND ENCEPUR ADVERSELY IMPACTED BY MEASURES TAKEN TO COMBAT COVID-19 AND DECLINE IN TRAVEL SEGMENT.COMPANY HAS TODAY DECIDED TO POSTPONE INITIATION OF PHASE 3 STUDY OF ITS RSV VACCINE CANDIDATE UNTIL 2022.PLANNING TO CONDUCT A HUMAN CHALLENGE TRIAL TO EVALUATE EFFICACY OF OUR PROMISING RSV VACCINE CANDIDATE.

Bavarian Nordic Q2 EBITDA Turns To Profit Of DKK 197 Million

Aug 26 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::Q2 EBITDA DKK 197 MILLION VERSUS LOSS DKK 83 MILLION YEAR AGO.REVENUES IN Q2 TOTALED DKK 700 MILLION.FULL-YEAR GUIDANCE ON REVENUE AND EBITDA MAINTAINED.SECURITIES, CASH AND CASH EQUIVALENTS AT YEAR-END IS NOW EXPECTED TO BE DKK 1,500 MILLION, DKK 150 MILLION HIGHER THAN PREVIOUSLY GUIDED..PLANS TO SUBMIT A SUPPLEMENT TO BLA TO EXTEND APPROVAL FOR BOTH FORMULATIONS OF MVA-BN, ANTICIPATED IN 2022.

Bavarian Nordic Announces Positive Topline Results From Phase 3 Clinical Study Of Freeze-Dried Smallpox Vaccine

Aug 24 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::REG-BAVARIAN NORDIC ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 CLINICAL STUDY OF FREEZE-DRIED SMALLPOX VACCINE.BAVARIAN NORDIC - COMPLETION OF STUDY WILL ENABLE CO TO SUBMIT A SUPPLEMENT TO BLA TO EXTEND APPROVAL FOR BOTH FORMULATIONS OF MVA-BN.BAVARIAN NORDIC - THREE LOTS OF MVA-BN INDUCED EQUIVALENT ANTIBODY RESPONSES MEETING PRIMARY ENDPOINT OF STUDY.BAVARIAN NORDIC - PHASE 3 STUDY CONFIRMED WITH NO SERIOUS ADVERSE REACTIONS REPORTED AMONG SUBJECTS.

ExpreS2ion's Joint Venture AdaptVac Signs Final License Agreement With Bavarian Nordic On COVID-19 Vaccine

July 22 (Reuters) - ExpreS2ion Biotech Holding AB <EXPRS2.ST>::EXPRES2ION'S JOINT VENTURE ADAPTVAC SIGNS FINAL LICENSE AGREEMENT WITH BAVARIAN NORDIC ON COVID-19 VACCINE.JOINT VENTURE ADAPTVAC HAS ENTERED INTO A FINAL LICENSE AGREEMENT WITH BAVARIAN NORDIC A/S.AGREEMENT WITH BAVARIAN NORDIC A/S TO LICENSE PROPRIETARY CAPSID VIRUS LIKE PARTICLE (CVLP) BASED SARS-COV-2 SUBUNIT VACCINE.EXPRES(2)ION WILL RETAIN UP TO EUR 2 MILLION, CORRESPONDING TO SEK 21 MILLION, OF COMMERCIAL MILESTONE PAYMENTS, WHICH ARE ESTIMATED TO BE RECOGNISED AS EXPRES(2)ION REVENUES DURING 2021 AND 2022.TOTAL DEAL VALUE, EXCLUDING ROYALTIES IS UP TO EUR 136 MILLION, CORRESPONDING TO SEK 1.4 BILLION.

Bavarian Nordic And AdaptVac Sign Final License Agreement On Covid-19 Vaccine

July 22 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::REG-BAVARIAN NORDIC AND ADAPTVAC SIGN FINAL LICENSE AGREEMENT ON COVID-19 VACCINE.PARTIES SIGNED A HEADS OF AGREEMENT IN MAY AND HAVE NOW CONCLUDED A LICENSE AGREEMENT THAT PROVIDES BAVARIAN NORDIC GLOBAL COMMERCIALIZATION RIGHTS TO COVID-19 VACCINE.AGREEMENT TO LICENSE ADAPTVAC'S PROPRIETARY CAPSID VIRUS LIKE PARTICLE (CVLP) TECHNOLOGY FOR CORONAVIRUSES, INCLUDING COVID-19 INDICATION.UNDER TERMS OF AGREEMENT, BAVARIAN NORDIC WILL MAKE AN UPFRONT PAYMENT OF EUR 4 MILLION TO ADAPTVAC, IN ADDITION TO POTENTIAL FUTURE DEVELOPMENT AND SALES MILESTONES AND TIERED ROYALTIES.AGREEMENT HAS NO IMPACT ON BAVARIAN NORDIC'S FINANCIAL GUIDANCE FOR 2020.AGREEMENT PROVIDES BAVARIAN NORDIC GLOBAL COMMERCIALIZATION RIGHTS TO COVID-19 VACCINE.WILL MAKE AN UPFRONT PAYMENT OF EUR 4 MILLION TO ADAPTVAC, IN ADDITION TO POTENTIAL FUTURE DEVELOPMENT AND SALES MILESTONES AND TIERED ROYALTIES.AGREEMENT SIGNED WITH ADAPTVAC, A JOINT VENTURE ESTABLISHED BY EXPRES2ION BIOTECHNOLOGIES AND NEXTGEN VACCINES SPUN OUT OF UNIVERSITY OF COPENHAGEN.

Bavarian Nordic Announces European Marketing Authorization For Ebola Vaccine

July 1 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::REG-BAVARIAN NORDIC ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR EBOLA VACCINE.EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVABEA (MVA-BN FILO) TOGETHER WITH ZABDENO (AD26.ZEBOV), WHICH COLLECTIVELY CONSTITUTE JANSSEN'S EBOLA VACCINE REGIMEN.APPROVAL FOLLOWS A POSITIVE OPINION BY CHMP OF EUROPEAN MEDICINES AGENCY IN MAY 2020.IN CONNECTION WITH APPROVAL OF MVABEA BY EUROPEAN COMMISSION, BAVARIAN NORDIC WILL RECEIVE A MILESTONE PAYMENT OF USD 10 MILLION UNDER LICENSE AGREEMENT WITH JANSSEN.PAYMENT WILL NOT IMPACT COMPANY'S FINANCIAL GUIDANCE FOR FULL YEAR 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up